• Annovis Bio reached full enrollment in its pivotal Phase 3 trial of buntanetap for early Alzheimer’s disease.
• Trial enrolled 850 patients across 83 U.S. sites, exceeding the original enrollment target.
• Top-line symptomatic data readout expected in Q1 2027; disease-modifying data readout targeted for Q1 2028.
• Company preparing for two FDA New Drug Application submissions, timed shortly after each respective readout.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-082341), on July 10, 2026, and is solely responsible for the information contained therein.